Based on the Thelansis market insight report on anorexia-cachexia Syndrome which provides a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.
https://thelansis.com/reports/anorexia-cachexia-syndrome-cs-market-insight-report/
The overall prevalence of Cachexia is ranging 0.19% to 0.23% in the USA and in the EU the overall prevalence ranges from 0.28% to 0.32%.
Comprehensive insight on patient segmentation based on age, sex, Critical Illness (AIDS, Cancer, COPD, Kidney Failure, Rheumatoid Arthritis, Chronic Heart Failure, Diabetes, and Other), Severity (mild, Moderate & Severe), Other Potential Mediators (Testosterone, Insulin-like growth factor I, Myostatin, Adrenal hormones ), Signs & Symptoms (Anorexia, Inflammation, Insulin resistance, Hypogonadism, Anemia and Others) , Clinical Manifestations, Treatment types (supportive therapy) has been provided into the epidemiology section of the Cachexia Syndrome (CS) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China.
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Helsinn Therapeutics, Pfizer, AVEO Pharmaceuticals, Inc., Active/ Faraday Pharmaceuticals, NGM Biopharmaceuticals, Inc, GlaxoSmithKline, GTx, NGM Biopharmaceuticals, Inc, Biogen, Janssen Research & Development, LLC, Celgene, Pinta Biotherapeutics, who are targeting the Cachexia Syndrome (CS) market. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of Cachexia Syndrome (CS) specifically for moderate to severe patients.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Myasthenia gravis (MG) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Tourette syndrome (TS) – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
Contact Information:
[email protected]
Tags:
PR-Wirein, Reportedtimes, Menafn, iCN Internal Distribution, Research Newswire, English
Add Comment